Actinium Ac 225 Lintuzumab

**Semantic type:** Amino Acid, Peptide, or Protein|Pharmacologic Substance

**Definition:** A radioimmunoconjugate consisting of the humanized monoclonal antibody lintuzumab conjugated to the alpha-emitting radioisotope actinium Ac 225 with potential antineoplastic activity. The monoclonal antibody moiety of actinium Ac 225 lintuzumab specifically binds to the cell surface antigen CD33 antigen, delivering a cytotoxic dose of alpha radiation to cells expressing CD33. CD33 is a cell surface antigen expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on myeloid leukemia cells.

**Synonyms:** - 225Ac-HuM195 - Actimab-A - Actinium (225Ac) Lintuzumab Satetraxetan - Actinium Ac 225 lintuzumab - Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195 - LINTUZUMAB SATETRAXETAN AC-225 - SGN-33 AC-225